Larvol Delta - Phase-II-Study-Assessing-Efficacy-and-Safety-of-Asciminib-in-Patients-With-Newly-Diagnosed-Chronic-Myeloid-Leukemia-in-Chronic-Phase

Scemblix (asciminib) - Novartis

http://clinicaltrials.gov/ct2/show/NCT06236724

Sep 26, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next